NEW YORK (
) hit a new 52-week high Thursday as it is currently trading at $85.56, above its previous 52-week high of $85.48 with 827,667 shares traded as of 11:30 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.
Alexion has a market cap of $13.68 billion and is part of the
industry. Shares are up 16.7% year to date as of the close of trading on Wednesday.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 89.9, below the average drugs industry P/E ratio of 92.5 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Alexion as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full
52-week high stocks
or get investment ideas from our